VHH Antibodies Targeting FimH for E. Coli Colonization Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for effective interventions to control E. coli infections, particularly targeting FimH antigens to reduce or inhibit E. coli colonization, which are associated with chronic conditions like Crohn's Disease and Ulcerative Colitis, and urinary tract infections.

Innovation Solution

Development of nanobodies, specifically VHH single domain antibodies, directed against FimH_SI and FimH_ST antigens, to neutralize or inhibit the activity of these targets, thereby reducing E. coli colonization and infection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antibodies are used to target FimH, then E. coli colonization can be inhibited, but the complexity of production and purification increases significantly

Engineering Contradiction:

Improveefficacy in inhibiting E. coli colonizationVSAvoidcomplexity of antibody production and purification

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the conventional antibody structure into a single variable domain (VHH), creating a nanobody that retains antigen-binding functionality while eliminating the need for complex heavy and light chain assembly. This segmentation enables simpler production in bacterial systems without requiring mammalian cell cultures.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent extracts only the essential antigen-binding variable domain from the complete antibody structure, discarding the constant regions and other non-essential components. This extraction results in a minimized protein structure that maintains therapeutic efficacy while dramatically simplifying production and purification processes.

Inventive Principle:

Principle #2Taking out (Extraction)

2Reliability

If full-size antibodies are used against FimH, then neutralization of E. coli activity is achieved, but the cost of manufacturing increases

Engineering Contradiction:

Improveneutralization of E. coli activityVSAvoidmanufacturing cost

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent employs a disposable, single-use nanobody structure that can be produced cheaply in bacterial systems. The nanobody's simplified structure allows for cost-effective manufacturing compared to full-size antibodies, which require expensive mammalian cell culture facilities and complex purification processes.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent changes the molecular weight parameter from full-size antibodies (150 kDa) to nanobodies (15 kDa), and alters the production system parameter from mammalian cells to bacterial expression systems. These parameter changes result in dramatically reduced manufacturing costs while maintaining neutralization efficacy.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If conventional antibodies are produced in mammalian cells, then proper folding and function are achieved, but production time and complexity increase

Engineering Contradiction:

Improveproper folding and functionVSAvoidproduction time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The nanobody structure is designed to be self-sufficient, folding correctly in simple bacterial systems without requiring the complex post-translational modification machinery of mammalian cells. This self-service capability eliminates the need for expensive and time-consuming mammalian cell culture processes while maintaining proper protein folding and function.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent substitutes the complex mammalian cell production system with a simpler bacterial expression system. This mechanical substitution replaces the need for sophisticated bioreactors, serum supplementation, and complex purification protocols with a streamlined bacterial fermentation and purification process that is faster and less expensive.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The nanobodies effectively reduce or block E. coli colonization, providing therapeutic and prophylactic benefits against E. coli infections, including Crohn's Disease, Ulcerative Colitis, and urinary tract infections, while modulating the immune response and acting as diagnostic tools.

Implementation Method 1

nanobodies directed against FimH_SI and FimH_ST antigens... capable of binding to their specific target protein and neutralizing or inhibiting the activity of their target

Methodology Applied

Scientific EffectAntigen-antibody binding:

Data Source

PatentUS20250304661A1VHH antibodies targeting fimh and methods of using the same

Publication Date: 2025.10.02 BIOMEDIT INC

AI summary

One or more antibodies, particularly nanobodies or VHH single domain antibodies, directed against one or more FimH targets with roles in E. coli colonization in animals are provided. The nanobodies are useful in reducing or inhibiting E. coli colonization or infection. Methods of treating and/or preventing E. coli infection and conditions related thereto are provided.